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Human keratinocytes (HKc) immortalized by human papillomavirus type 16 DNA (HKc/HPV16) progress toward malignancy
through growth factor-independent (HKc/GFI) and differentiation-resistant stages (HKc/DR). This progression is associated
with a loss of sensitivity to growth inhibition by both all-trans-retinoic acid (RA) and transforming growth factor-b (TGF-b). In
the accompanying article (Borger et al., 2000, Virology 270, 397–407), we demonstrate that RA resistance in HKc/HPV16
arises despite functional nuclear retinoid receptors and that TGF-b mediates growth inhibition by RA. To investigate the basis
for the loss of TGF-b sensitivity during in vitro progression of HKc/HPV16, we explored the expression of TGF-b receptors
type I and type II in independently derived HKc/HPV16 lines and their corresponding HKc/GFI and HKc/DR derivatives. While
TGF-b receptor type II mRNA levels were unchanged during progression, mRNA levels for TGF-b receptor type I decreased
dramatically as the cells became TGF-b resistant. At the HKc/DR stage, loss of TGF-b receptor type I mRNA, compared to
low-passage cells, ranged from 55 to 87% in four HKc/HPV16 lines examined. Immunohistochemistry, using anti-TGF-b
receptor type I antibodies, confirmed a loss of TGF-b receptor type I expression in HKc/DR. Reintroduction of the
TGF-b-receptor type I into TGF-b-resistant HKc/DR completely restored growth inhibition by TGF-b. Southern blot analysis
of DNA extracted from normal HKc, HKc/HPV16, and HKc/DR ruled out any gross changes in the TGF-b receptor type I gene.
The activity of the TGF-b receptor type I promoter, cloned upstream of a luciferase reporter gene, was decreased in HKc/DR,
to an extent comparable to the decrease in mRNA levels for the TGF-b receptor type I. Thus, TGF-b resistance at late stages
of HPV16-mediated transformation of HKc is the result of a loss of expression of TGF-b receptor type I. © 2000 Academic Press
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sINTRODUCTION
In our in vitro model system for human papillomavirus
ype 16 (HPV16)-mediated multistep carcinogenesis, nor-
al human keratinocytes (HKc) are immortalized by
ransfection with HPV16 DNA (HKc/HPV16) and then un-
ergo malignant conversion through a series of pheno-
ypically defined and reproducible “steps.” At early pas-
ages, HKc/HPV16 retain many features characteristic of
ormal HKc, including a requirement for epidermal
rowth factor (EGF) and bovine pituitary extract (BPE) for
roliferation and the ability to terminally differentiate in
esponse to serum and high calcium (Pirisi et al.,
987,1988). In the next step of our progression model,
rowth factor-independent sublines (HKc/GFI) that no
onger require EGF and BPE for proliferation are selected
rom HKc/HPV16 (Pirisi et al., 1988; Zyzak et al., 1994).
ext, sublines that no longer respond to calcium- and
erum-induced differentiation (HKc/DR) are selected
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408rom HKc/GFI (Pirisi et al., 1988). In the final step, malig-
ant conversion of HKc/DR is achieved by transfection
ith viral Harvey ras or herpes simplex virus type 2 DNA
DiPaolo et al., 1989,1990). The phenotypic and biochem-
cal characteristics progressively acquired by HKc/
PV16 in this model are similar to those found in cell
ines established from human tumors. For example, the
oss of requirement for EGF and BPE in HKc/GFI paral-
els the reduced growth factor/serum requirements often
ound in human tumor-derived cell lines established from
wide variety of neoplasms (Anzano et al., 1989; Hofer et
l., 1991; Macaulay et al., 1990; Ohmura et al., 1990; Reiss
t al., 1991). Cancer cells also commonly show a lack of
ifferentiation, like HKc/DR. Interestingly, it has been
ound that cervical cancer cells, much like HKc/GFI,
xpress increased levels of the EGF receptor (Bauknecht
t al., 1989; Goppinger et al., 1989; Gullick et al., 1986).
HPV16-immortalized HKc are initially highly sensitive
o the growth inhibitory effects of all-trans-retinoic acid
RA) and transforming growth factor-b (TGF-b). However,
n the accompanying report we demonstrate that as
Kc/HPV16 undergo in vitro progression they lose sen-
itivity to growth inhibition by both RA and TGF-b (Borger
t al., 2000). In addition, we found that RA resistance in
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409TGF-b RECEPTOR TYPE I LOSS IN HPV16-TRANSFORMED KERATINOCYTESHKc/HPV16 arises despite functional nuclear retinoid
receptors and that TGF-b mediates growth inhibition by
RA (Borger et al., 2000). TGF-b elicits its biologic effects
through a unique receptor system composed of het-
erodimeric complexes of two distantly related, ubiqui-
tously expressed, transmembrane serine/threonine ki-
nase receptors, referred to as TGF-b receptors type I and
ype II (Attisano et al., 1994; Miyazono et al., 1994; Mas-
sague, 1998). Receptor activation occurs upon binding of
TGF-b to the type II receptor, a constitutively active ki-
nase. Upon ligand binding, the type II receptor recruits
and transphosphorylates the type I receptor in its gly-
cine- and serine-rich domain. Once phosphorylated, the
type I receptor is activated and propagates the signal to
downstream substrates (Wrana et al., 1992,1994). Recent
studies have demonstrated the importance of the Smad
family of proteins as essential intracellular components
of the TGF-b signaling pathway that are responsible for
ransducing the signal from the TGF-b receptors at the
cell surface to the nucleus (see Heldin et al., 1997 for a
review).
To begin to identify what point(s) in the TGF-b signal
transduction pathway may be disrupted as HKc/HPV16
become TGF-b resistant, we explored the expression of
RNA for TGF-b receptors type I and type II in HKc/
PV16 lines and their corresponding HKc/GFI and
Kc/DR derivatives. While TGF-b receptor type II mRNA
evels were unchanged during progression, mRNA levels
or TGF-b receptor type I decreased dramatically as
HKc/HPV16 became TGF-b resistant. In addition, reintro-
uction of the TGF-b receptor type I into TGF-b-resistant
HKc/DR completely restored growth inhibition by TGF-b,
confirming that the loss of the TGF-b receptor type I is
ey to the loss of TGF-b sensitivity observed during in
vitro progression of HPV16-immortalized HKc.
RESULTS
Reduced expression of TGF-b receptor type I but not
type II mRNA in TGF-b-resistant HKc/HPV16
As shown in the accompanying paper, HKc/HPV16
ecome increasingly resistant to TGF-b during in vitro
progression (Borger et al., 2000). To investigate whether
a loss or reduction in mRNA expression of TGF-b recep-
tors type I or II may contribute to TGF-b resistance in this
model system, we conducted ribonuclease protection
assays (RPAs) with riboprobes specific for the TGF-b
receptors type I or type II, using total RNA extracted from
independently derived HKc/HPV16 lines and their corre-
sponding HKc/GFI and HKc/DR counterparts. As shown
in Fig. 1, a dramatic decrease in the levels of TGF-b
receptor type I mRNA occurs during progression in all
four of the HKc/HPV16 lines examined. Based on densi-
tometric scanning of the autoradiograms shown in Fig. 1,
the extent of loss of expression of TGF-b receptor type I
mRNA at the HKc/DR stage (compared to low-passageHKc/HPV16) was 87% in HKc/HPV16d-2, 85% in HKc/
HPV16d-4, 76% in HKc/HPV16d-5, and 55% in HKc/
HPV16d-1. In contrast, no reduction in the levels of the
TGF-b receptor type II mRNA was found during progres-
ion (Fig. 2). In fact, HKc/DR expressed from 95% (HKc/
PV16d-1) to 166% (HKc/HPV16d-4) of the levels of
RNA for the type II receptor found in their low-passage
ounterparts (Fig. 2).
educed expression of TGF-b receptor type I protein
in HKc/DR
To compare the protein levels of TGF-b receptor type I
n low-passage HKc/HPV16 to HKc/DR, we used immu-
ohistochemistry. Intense staining for the TGF-b receptor
type I was evident in low-passage HKc/HPV16 but not in
HKc/DR (Fig. 3). We found no changes in staining for the
TGF-b receptor type II between low-passage HKc/HPV16
FIG. 1. Reduced expression of TGF-b receptor type I mRNA during in
itro progression of HPV16-immortalized HKc. RPAs were conducted
ith a riboprobe specific for the TGF-b receptor type I (TGF-bRI) or 28S
rRNA, using RNA isolated from low- (passage 14) and high- (passage
157) passage HKc/HPV16d-1, low- (passage 8) and high- (passage 111)
passage HKc/HPV16d-2, low- (passage 16) and high- (passage 105)
passage HKc/HPV16d-4, low- (passage 8) and high- (passage 100)
passage HKc/HPV16d-5, and their corresponding HKc/GFI and HKc/DR
lines. All cells were incubated in GFDM for 24 h before they were
harvested for RNA extraction.and HKc/DR (data not shown). Thus, the loss of immu-
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410 MI ET AL.noreactivity for TGF-b receptor type I protein in HKc/DR
paralleled the reduced steady-state levels of TGF-b re-
eptor type I mRNA.
he structure of the TGF-b receptor type I gene is
not altered during in vitro progression of HKc/HPV16
To explore whether gross structural changes/rear-
rangements in the gene for the TGF-b receptor type I, or
ts loss, may be responsible for reduced mRNA expres-
ion of the receptor during progression, we isolated
enomic DNA from normal HKc and the HKc/HPV16d-1
ine at different stages of progression and conducted
FIG. 2. TGF-b receptor type II mRNA levels do not change during in
itro progression of HPV16-immortalized HKc. RPAs were conducted
ith a riboprobe specific for TGF-b receptor type II (TGF-bRII) or 28S
rRNA, using RNA isolated from low- (passage 14) and high- (passage
157) passage HKc/HPV16d-1, low- (passage 16) and high- (passage
105) passage HKc/HPV16d-4, and their corresponding HKc/GFI and
HKc/DR lines. All cells were incubated in GFDM for 24 h before they
were harvested for RNA extraction.
FIG. 3. Immunostaining for TGF-b receptor type I in low-passage HKc
(HKc/DR TbRI). Cells were cultured on 100-mm tissue culture dishes unti
ntibodies against the TGF-b receptor type I, as described under Materials aouthern blot analysis after digestion with either EcoRI
r HincII. As shown in Fig. 4, the TGF-b receptor type I
gene is present at all stages of progression and there is
no evidence of gross structural alterations. Identical re-
sults were obtained using DNA isolated from the HKc/
HPV16d-4 line (data not shown).
d-1, HKc/DRd-1, and HKc/DRd-1 reexpressing the TGF-b receptor type
FIG. 4. Southern blot analysis of the TGF-b receptor type I gene in
ormal HKc and HKc/HPV16d-1 at various stages of in vitro progres-
ion. Genomic DNA (10 mg) obtained from normal HKc, low-passage
HKc/HPV16 (passage 13), high-passage HKc/HPV16 (passage 152),
HKc/GFI, or HKc/DR was digested overnight with either EcoRI (top) or
HincII (bottom). The digest was separated by gel electrophoresis and
transferred to a nitrocellulose membrane. The membrane was then
hybridized with a 32P-radiolabeled full-length TGF-b receptor type I
probe./HPV16
l about 80% confluence and then were immunostained with specific
nd Methods.
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411TGF-b RECEPTOR TYPE I LOSS IN HPV16-TRANSFORMED KERATINOCYTESReintroduction of the TGF-b receptor type I restores
ensitivity to growth inhibition by TGF-b in HKc/DR
A mammalian expression vector (pcDNA3.1/Zeo (1))
containing the full-length coding sequence for the TGF-b
receptor type I or vector alone was transfected into
HKc/DR and clones were selected for resistance to Zeo-
cin. As shown by immunohistochemistry, the cells trans-
fected with the TGF-b receptor type I expression vector
reexpressed the receptor at levels approaching that
FIG. 5. TGF-b-mediated growth inhibition is restored upon transfec-
ion of HKc/DR with a TGF-b receptor type I expression construct. An
expression vector containing either the full-length coding sequence for
the TGF-b receptor type I or empty vector alone was transfected into
he HKc/DR derivative of HKc/HPV16d-1 and clones resistant to Zeocin
ere selected. The extent of cell proliferation following 72 h of TGF-b1
reatment of the HKc/DR cells reexpressing the TGF-b receptor type I
(HKc/DR TBRI), vector-transfected cells (HKc/DR Vect.), low-passage
HKc/HPV16d-1 (HKc/HPV16 Low), and the HKc/DR derivative of HKc/
HPV16d-1 was then determined using an MTS-based proliferation as-
say (CellTiter AQueous One Solution Cell Proliferation Assay, Promega).
Values represent the means 6 SEM of eight replicates per sample.
FIG. 6. TGF-b receptor type I promoter activity decreases during pro
vitro progression were transiently cotransfected with a luciferase repo
ype I promoter (TbRI-Promoter) or an SV40 promoter (pGL3-Promoteractivity was measured using the Promega Dual Luciferase Assay and was n
means 6 SEM of triplicate independent transfections.found in low-passage HKc/HPV16 (Fig. 3, compare first
and third panels). TGF-b1 sensitivity of the clones reex-
pressing the TGF-b receptor type I was compared to
vector controls, low-passage HKc/HPV16, and HKc/DR.
As shown in Fig. 5, reintroduction of the TGF-b receptor
type I fully restored sensitivity to the growth inhibitory
effects of TGF-b, thus providing strong support to the
hypothesis that a loss of the TGF-b receptor type I is key
to the loss of sensitivity to TGF-b found in HKc/DR.
TGF-b receptor type I promoter activity is reduced
in HKc/DR
A 1.4-kb proximal fragment of the promoter region of
the TGF-b receptor type I gene was cloned into the
uciferase reporter plasmid pGL3-Basic and was used to
ransiently transfect HKc/HPV16d-1 and d-2 at different
tages of in vitro progression. Basal luciferase activity
was determined 48 h after transfection. As shown in Fig.
6, luciferase activity was decreased in both cell lines
during progression so that by the HKc/DR stage, loss of
TGF-b receptor type I promoter activity was approxi-
mately equivalent to the reduced levels of the TGF-b
receptor type I mRNA found at the HKc/DR stage. The
reduction in TGF-b receptor type I promoter activity dur-
ing progression was not the result of a general repres-
sion of transcription, since luciferase activity of a control
vector containing an SV40 promoter remained relatively
constant throughout progression (Fig. 6).
DISCUSSION
An important step in the development of malignant
disease involves a loss of sensitivity to TGF-b, which is
elieved to play an important role in suppressing tumor-
n of HKc/HPV16. HKc/HPV16d-1 (A) or d-2 (B) at different stages of in
smid under transcriptional control of either the human TGF-b receptor
Renilla luciferase control vector. At 48 h posttransfection, luciferasegressio
rter pla
) and aormalized against the Renilla luciferase control. Values represent the
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412 MI ET AL.igenicity (Brattain et al., 1996). In the accompanying pa-
er we demonstrated that HPV16-immortalized HKc ac-
uired TGF-b resistance during in vitro progression
Borger et al., 2000). Mechanisms leading to escape from
utocrine or paracrine growth control by TGF-b during
arcinogenesis include a loss of functional TGF-b recep-
tors type I and/or type II, as well as downstream signal-
ing components such as the Smads. In the present study,
we demonstrate that TGF-b resistance at late stages of
PV16-mediated transformation of HKc correlates with a
oss of expression of the TGF-b receptor type I, while
mRNA levels for the TGF-b receptor type II are un-
changed.
Previous studies have shown that genetic changes/
mutations in the TGF-b receptor type II gene are rather
ommon in colon, gastric, and ovarian cancers (Brattain
t al., 1996; Lynch et al., 1998; Markowitz et al., 1995;
Myeroff et al., 1995; Ohue et al., 1996; Park et al., 1994;
Parsons et al., 1995), but not endometrial cancers (My-
eroff et al., 1995), and that malignancy is directly asso-
ciated with a loss of TGF-b receptor type II expression
Wang et al., 1995). Mutations in the TGF-b receptor type
II gene cluster predominantly in a polyadenine tract in
exon 3 and lead to a premature STOP codon that pro-
duces a truncated receptor without serine/threonine ki-
nase activity. These mutations appear to be characteris-
tic of, and are relatively confined to, the mismatch repair
defect found in hereditary nonpolyposis colon cancers
and other cancers with microsatellite instability (MSI).
TGF-b receptor type II mutations are a late event in
uman MSI colon adenomas and tightly correlate with
he transition of benign adenoma to malignant carci-
oma (Grady et al., 1998). Missense mutations within the
inase domain of the TGF-b receptor type II gene have
been identified in human head and neck squamous cell
carcinoma cell lines (Garrigue-Antar et al., 1995) and in
primary ovarian carcinomas (Lynch et al., 1998). Recently
TGF-b receptor type II expression in head and neck
ancers was found to be inversely correlated with dis-
ase aggressiveness (Muro-Cacho et al., 1999). How-
ever, TGF-b resistance in most cases is not linked to
mutations in the TGF-b receptor type II gene. For exam-
le, mutations in the TGF-b receptor type II gene were
ot found in primary human esophageal cancers that
xhibited low or undetectable transcripts for the receptor
nd loss of receptor expression was independent of
athologic tumor stage, histologic subtype, or outcome
f patients with esophageal cancer (Garrigue-Antar et al.,
996). In addition, studies by Vincent et al. (1997) failed to
ind TGF-b receptor type II mutations in TGF-b-resistant
human cancer cell lines from various tissues, including
the cervix. In this regard, the HPV18-positive cell line
C4-1 and HPV16-positive lines CaSki and SiHa showed
no evidence of TGF-b receptor type II mutations (Vincent
et al., 1997) and C4-1, CaSki, SiHa, and HeLa express
normal levels of mRNA for the type II receptor (Garrigue- WAntar et al., 1995; Kang et al., 1998). These results are
consistent with our RPA results that failed to detect any
changes in mRNA levels for the TGF-b receptor type II in
ur model of HPV16-mediated human cell carcinogene-
is. However, TGF-b receptor type II mRNA was not
expressed in the ME-180 and C-33A cervical carcinoma
cell lines (Kang et al., 1998). Southern blot analysis found
hat loss of TGF-b receptor type II expression in ME-180,
but not C-33A, was due to a homologous deletion of the
entire receptor gene (Kang et al., 1998). A mutation in the
TGF-b receptor type II gene promoter was associated
ith a loss of receptor mRNA expression in the vulvar
quamous cell carcinoma line A431 (Munoz-Antonia et
l., 1996).
We consistently found a decrease in the expression of
he TGF-b receptor type I at late stages of in vitro pro-
ression of HPV16-transformed HKc and believe that its
oss is a critical component of TGF-b resistance in our
odel of human cell carcinogenesis. Consistent with our
esults are several other studies linking attenuated ex-
ression of TGF-b receptor type I with resistance to
growth inhibition by TGF-b and tumor progression in
arious tissues and cancer sites, including the cervix.
kamoto and Oyasu (1997) reported that LMC19, a highly
nvasive and metastatic rat bladder carcinoma cell line
hat is resistant to the growth inhibitory effects of TGF-b,
expressed undetectable levels of TGF-b receptor type I
RNA. Reintroduction of the receptor restored TGF-b
sensitivity and reverted the malignant phenotype to a
less aggressive phenotype (Okamoto and Oyasu, 1997).
Also, loss of expression of the TGF-b receptor type I in
bladder transitional cell carcinoma patients was associ-
ated with an increased probability of tumor progression
and a decreased probability of survival, suggesting that
receptor loss may be a potential prognostic marker (To-
kunaga et al., 1999). Using the human colon carcinoma
cell line GEO, Wang et al. (1996) correlated a loss of type
I receptor expression to malignant progression. Further-
more, loss or reduced expression of mRNA for the type I
receptor has been reported in human colorectal cancer
tissue (Matsushita et al., 1999). Southern blot analysis
has demonstrated that the TGF-b-resistant human pros-
tate cancer cell line LNCaP has a genetic alteration in
the TGF-b receptor type I gene that led to a loss of
receptor expression and transient transfection of LNCaP
with TGF-b type I receptor DNA restored TGF-b sensitiv-
ity (Kim et al., 1996a). However, results by others suggest
that a loss of TGF-b receptor type II leads to a loss of
ensitivity to TGF-b1 in LNCaP, as overexpression of the
GF-b receptor type II can restore TGF-b1 sensitivity and
signaling in LNCaP (Guo and Kyprianou, 1998). Immuno-
histochemical studies show an inverse correlation be-
tween the levels of expression of TGF-b receptors type I
nd/or type II and the histopathological grade of human
rostate cancer tissue (Kim et al., 1996b; Guo et al., 1997;
illiams et al., 1996) and loss of expression of the TGF-b
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413TGF-b RECEPTOR TYPE I LOSS IN HPV16-TRANSFORMED KERATINOCYTESreceptor type I has been associated with advanced clin-
ical tumor stage, decreased 4-year survival rate, and
increased serological recurrence rate after radical pros-
tatectomy (Kim et al., 1998). Attenuated expression of
TGF-b receptor type I has also been reported in TGF-b-
esistant human pancreatic cancer cell lines (Baldwin et
l., 1996), with reintroduction of the receptor restoring
GF-b responsiveness (Wagner et al., 1998). Genetic
lterations of the TGF-b receptor genes have also been
ound in human cervical carcinoma (Chen et al., 1999)
nd pancreatic and biliary adenocarcinomas (Goggins et
l., 1998). In human chronic lymphocytic leukemia, loss
f cell surface TGF-b receptor type I was found but
mRNA levels were unchanged (DeCoteau et al., 1997).
It is therefore apparent that a variety of mechanisms
may lead to a loss of TGF-b receptor expression or
unction during carcinogenesis. Most frequently, a loss of
GF-b receptor expression has been observed in the
bsence of gross alterations in the structure of the TGF-b
receptor genes. Using Southern blot analysis, we failed
to detect gross alterations/rearrangements in the TGF-b
receptor type I gene in TGF-b-resistant HKc/HPV16, in-
dicating that loss of receptor mRNA expression must
occur through mechanisms other than gene deletion in
our model. However, we cannot discount the possibility
that some genetic alterations in the TGF-b receptor type
gene may occur during in vitro progression of HKc/
PV16 that lead to reduced receptor expression. In this
egard, Chen et al., (1999) have recently reported some
tructural alterations of the TGF-b receptor genes in
uman cervical carcinoma, including several novel poly-
orphisms in the TGF-b receptor type I gene, one of
which may predispose for the development of cervical
carcinoma. Studies by Ammanamanchi et al. (1998)
found that transcriptional repression of TGF-b receptor
ype II in estrogen receptor-positive breast cancer cells
as the result of suboptimal levels of the transcription
actor Sp1, while another study found a TGF-b receptor
ype I kinase mutant associated with metastatic breast
ancer (Chen et al., 1998). Our observation that TGF-b
receptor type I promoter activity declines during progres-
sion of HKc/HPV16 is consistent with a loss of, or
changes in, the activity of transcription factors, such as
Sp1, that are important for transcription of the TGF-b
receptor type I gene. Cyclin expression may also influ-
ence TGF-b receptor expression. For example, suppres-
sion of cyclin D1 levels in COLO-357 cells was found to
be associated with down-regulation of the TGF-b recep-
tor type I (Kornmann et al., 1999). TGF-b resistance and
ranscriptional repression of the TGF-b receptor type I in
some human gastric cancers have been found to be the
result of hypermethylation of a CpG island in the 59
region of the type I receptor gene (Kang et al., 1999). We
re currently determining whether changes in cellular
evels of transcription factors, cyclins, or levels of meth-
lation of the TGF-b receptor type I promoter occur dur-ng HPV16-induced transformation of HKc that may result
n reduced TGF-b receptor type I expression.
It is important to point out that a partial loss of TGF-b
sensitivity in our in vitro model system occurred in most
ases prior to any detectable loss of the TGF-b receptor
type I mRNA as measured by RPA. This suggests that
more than one mechanism may contribute to the pro-
gressive loss of TGF-b sensitivity during in vitro progres-
sion, with reduced TGF-b receptor type I expression
being responsible for the complete TGF-b resistance
bserved at late stages. A decreased expression of
GF-b1 has been observed in neoplastic epithelium and
increased expression of extracellular TGF-b1 in stroma
of cervical cancer, indicating that these cells may be
partially or totally resistant to TGF-b1 (Comerci et al.,
1996). In addition, consistent with our findings, De Geest
et al. (1994) found that while normal cervical cells were
highly sensitive to growth inhibition by TGF-b1, HPV-
ositive cell lines derived from cervical intraepithelial
eoplasia were less sensitive, and newly established
ervical carcinoma cell lines were resistant. These re-
ults again support what we find in our in vitro model and
rovide additional evidence that complete resistance to
GF-b is likely a rather late event in the development of
cervical carcinoma.
We are actively pursuing the possibility that signal
transduction events downstream of the type I receptor
may be involved in the earliest stages of TGF-b resis-
ance, including changes in the Smad family of proteins
hat serve the important function of directly transmitting
he TGF-b signal from the type I receptor into the nucleus
(Heldin et al., 1997; Hoodless and Wrana, 1998; Mas-
sague, 1998). The possibility that the products of the
HPV16 oncogenes E6 and E7 may interact with and alter
Smad activity has been raised with the recent report that
the adenovirus oncoprotein E1A interacts specifically
with the receptor regulated Smads (Smad1, Smad2, and
Smad3), but not Smad4 or Smad6, thereby directly inhib-
iting TGF-b signaling (Nishihara et al., 1999). We thus feel
that it is likely that the HPV16 oncoproteins themselves
play an important role in mediating the partial resistance
to TGF-b that we observe at the earliest stages of our
model and we are actively exploring this possibility. In
addition, it will be of extreme interest to investigate
whether a loss of TGF-b receptor type I can be detected
in vivo as cells progress from cervical intraepithelial
neoplasia to cervical carcinoma and whether or not such
loss correlates with the stage of the lesion and/or can be
used as an indicator of progression.
MATERIALS AND METHODS
Cell culture and cell lines. Normal HKc were isolated
from newborn foreskins and cultured in serum-free
MCDB153-LB medium. Details concerning the establish-
ment of the various HKc/HPV16 cell lines and their HKc/
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414 MI ET AL.GFI and HKc/DR counterparts are described in the ac-
companying article (Borger et al., 2000).
RNA analysis. The levels of mRNA for TGF-b receptors
type I and II were measured by RPAs using an RPAII kit
(Ambion) according to the instructions provided by the
manufacturer. Templates for the synthesis of riboprobes
specific for the TGF-b receptors type I (nucleotides 815–
984) (Franzen et al., 1993) and type II (nucleotides 933–
1190) (Lin et al., 1992) were produced by PCR or reverse
transcriptase/PCR and cloned into pGEM-T Easy (Pro-
mega). Molecular size standards and housekeeping con-
trol templates for the RPAs were obtained from Ambion.
Immunostaining for TGF-b receptors type I and II. Low-
assage HKc/HPV16d-1, HKc/DRd-1, and HKc/DRd-1 re-
xpressing the TGF-b type I receptor (HKc/DR TbRI)
were cultured in 100-mm dishes until approximately 80%
confluent. Cells were washed in ice-cold phosphate-
buffered saline (PBS), fixed in 2% paraformaldehyde in
PBS at room temperature for 10 min, followed by washing
with PBS. Cells were then incubated in 0.3% hydrogen
peroxide in water for 20 min, washed with PBS, and then
incubated for 20 min in diluted normal blocking serum
(Vectastain Elite ABC Kit from Vector Laboratories). Cells
were then incubated for 30 min with 0.1 mg/ml of anti-
TGF-b receptor type I IgG (a rabbit polyclonal antibody
raised against a polypeptide corresponding to amino
acids 158–179 of the precursor form of human TGF-b
receptor type I obtained from Santa Cruz Biotechnology,
sc-398) or anti-TGF-b receptor type II IgG (a rabbit poly-
lonal antibody obtained from Santa Cruz Biotechnology,
c-220) in PBS containing 0.1% bovine serum albumin.
ells were then washed in PBS, incubated for 30 min
ith biotinylated secondary antibody (anti-rabbit IgG
rom Vector Laboratories), washed again with PBS, and
ncubated with Vectastain Elite ABC Reagent (Vector
aboratories) for 30 min. Cells were then washed with
BS, incubated with peroxidase substrate solution (Vec-
or Laboratories) for 2 to 3 min, rinsed with tap water,
ounted, and observed by light microscopy.
Southern blot analysis. Genomic DNA (10 mg), isolated
rom the different stages of the HKc/HPV16d-1 or d-4
ines, was digested to completion with either EcoRI or
incII and the digests were subjected to electrophoresis
n 0.7% agarose gels. Following transfer to nitrocellulose
embranes, hybridization was conducted using a 32P-
labeled full-length (1.5-kb) TGF-b receptor type I cDNA
using standard procedures and bands were visualized
by autoradiography.
Stable transfection of HKc/DR with a mammalian ex-
pression vector encoding TGF-b receptor type I. A TGF-b
receptor type I cDNA containing the full-length coding
sequence (a gift from Dr. C.-H. Heldin) was cloned into
the mammalian expression vector pcDNA3.1/Zeo (1) (In-
itrogen) and the resulting construct was transfected into
GF-b-resistant HKc/DR using the poly-L-ornithinemethod (Nead and McCance, 1995). Selection was madein serum-free, bovine pituitary extract-free, low-calcium
medium containing 50 mg/ml Zeocin (Invitrogen). Zeocin-
resistant colonies were cloned and expanded.
Cell proliferation assay. Low-passage HKc/HPV16d-1,
HKc/DRd-1, HKc/DRd-1 reexpressing the TGF-b receptor
ype I, and HKc/DRd-1 transfected with pcDNA3.1/Zeo
1) were plated at 10,000 cells per well in a 96-well plate.
t 6 h postplating, cells were treated without or with
arious concentrations of TGF-b1 for 72 h with refeeding
every 24 h. At 72 h posttreatment, the extent of cell
proliferation/viability was determined using the CellTiter
96 AQueous One Solution Cell Proliferation Assay (Pro-
mega) according to the manufacturer’s instructions.
TGF-b receptor type I promoter reporter construct. A
1.45-kb fragment of the TGF-b receptor type I promoter
21398 to 150; Bloom et al., 1996) was amplified by PCR
rom normal HKc genomic DNA using the forward primer
9-ACGCCTTTTCCCTTTTCATCTCCC-39 and the reverse
rimer 59-AGCACGAGGAGGAGCAGCCGG-39 and was
loned into the EcoRV restriction site of pBluescript
K(1) (Stratagene). The ATG initiation codon was mu-
ated to produce a 39 HindIII site (italics) using the fol-
owing primers: forward, 59-CTCCCGGAAGGAAGCCT-
CAC-39, and reverse, 59-AAGCTTGGTCCCGCCGC-
ACC-39. The subsequent ;1.4-kb TGF-b receptor type I
promoter fragment (21379 to 16) was then cloned into
the EcoRV site of pBluescript SK(1), released by diges-
tion with HindIII, and then subcloned into the pGL3-Basic
luciferase vector (Promega) as TbRI-Promoter. The se-
quence was confirmed using the T7 Sequenase Quick-
Denature Plasmid Sequencing Kit (Amersham), accord-
ing to the manufacturer’s instructions.
Transient transfection of TGF-b receptor type I pro-
oter reporter construct into HKc/HPV16 at different
tages of in vitro progression. Cells were plated at a
ensity of 0.5 3 106 per 60-mm dish, and at 24 to 48 h
ostplating (30–40% confluence), they were transiently
otransfected using Lipofectace (Gibco BRL) with 2 mg of
either the TbRI-Promoter luciferase construct or the
GL3-Promoter luciferase construct (containing an SV40
romoter; Promega) and 2 ng of a control Renilla lucif-
rase vector pRL-SV40 (Promega). At 48 h posttransfec-
ion, luciferase activity was measured using the Promega
ual Luciferase Assay and was normalized against pRL-
V40 activity.
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